Question to Grok: Did Ireland steal the entire United States pharmaceutical industry as Trump claimed?
“No, Ireland did not "steal" the entire United States pharmaceutical industry. This claim seems to stem from exaggerated rhetoric rather than factual evidence. What has happened is that Ireland has become a major hub for pharmaceutical manufacturing and exports, attracting many U.S.-based companies due to its favorable economic conditions, not through theft or coercion.
Ireland’s rise in the pharmaceutical sector is well-documented. The country is one of the world’s top exporters of pharmaceuticals, ranking third globally in 2021 with $70.6 billion in exports, behind Germany ($115 billion) and Switzerland ($90.2 billion), but ahead of the U.S. ($81.5 billion) in some metrics. This success is largely due to a deliberate strategy starting in the 1960s, when Ireland began attracting foreign direct investment (FDI) from U.S. and other multinational pharmaceutical companies. Companies like Pfizer, AbbVie, and Johnson & Johnson have established significant operations there, employing tens of thousands and contributing to Ireland’s economy, where pharma accounts for about 45% of goods exports as of 2024.
The attraction isn’t theft—it’s economics. Ireland offers a low corporate tax rate (historically 12.5%, now shifting to 15% under global agreements), a skilled workforce, and access to the European Union market. U.S. companies often set up subsidiaries in Ireland to manufacture drugs, sometimes shifting intellectual property (IP) there to reduce tax liabilities in the U.S. This practice, often called "tax inversion" or profit-shifting, allows firms to "import" drugs back to the U.S. at higher costs while booking profits in Ireland. Critics argue this disadvantages the U.S. Treasury and consumers, but it’s a legal strategy enabled by U.S. tax policy gaps, not an Irish heist.
Claims on platforms like X suggesting Ireland "has the entire U.S. pharmaceutical industry in its grasp" oversimplify the situation. The U.S. still has a massive domestic pharma presence—think of giants like Merck or Eli Lilly—and remains the largest market for drug consumption, generating $660 billion in revenue in 2025 projections. Ireland’s role is more about production and tax optimization, not ownership or control. In 2019, U.S. pharma imports were $151 billion, with Ireland and Switzerland as key sources, but this reflects strategic outsourcing, not a takeover.
The idea of "stealing" also ignores mutual benefits. U.S. companies gain tariff-free access to the EU and other markets from Ireland, boosting their global reach. Meanwhile, Ireland’s economy grows, employing over 50,000 in the sector. It’s a symbiotic relationship, though one that’s sparked debate about U.S. tax reform and trade deficits (e.g., $93 billion in pharma trade deficit in 2020).
So, no grand theft occurred—just smart positioning by Ireland and profit-driven decisions by U.S. firms, enabled by policy on both sides of the Atlantic. The narrative of "stealing" is more political hyperbole than reality.”